Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion

British Journal of Ophthalmology

Volumn 90, Issue 7, 2006, Pages 911-915

  Mahmoud, Tamer H ^a,b   Peng, Y W ^b   Proia, A D ^b   Davidson, M ^c   Deramo, V A ^b,d   Fekrat, S ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d Long Island Vitreoretinal Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DRUG PENETRATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REPERFUSION; RETINA ARTERY; RETINA VEIN; SWINE;

ANIMALS; CAPILLARY PERMEABILITY; IMMUNOHISTOCHEMISTRY; INJECTIONS; MODELS, ANIMAL; RECOMBINANT PROTEINS; RETINAL VEIN; RETINAL VEIN OCCLUSION; SWINE; TISSUE PLASMINOGEN ACTIVATOR; VITREOUS BODY;

EID: 33745665553     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.089037     Document Type: Article

References (30)

1. Clarkson J. Central retinal vein occlusion. In: Ryan S, eds. Retina. St Louis: Mosby, 1994:1379.
2. Green WR, Chan CC, Hutchins GM, et al. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981;79:371-422.
3. Oncel M, Peyman GA, Khoobehi B. Tissue plasminogen activator in the treatment of experimental retinal vein occlusion. Retina 1989;9:1-7.
4. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc 1996;94:471-504.
5. Hattenbach LO, Steinkamp G, Scharrer I, et al. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 1998;212:394-8.
6. Hattenbach LO, Wellermann G, Steinkamp GW, et al. Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. Ophthalmologica 1999;213:300-6.
7. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
8. Vallee JN, Aymard A, Paques M, et al. Value of local ophthalmic artery fibrinolysis in severe forms of central retinal vein occlusion. J Radiol 2001;82:137-44.
9. Weiss JN. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol 1998;126:142-4.
10. Weiss JN. Retinal surgery for treatment of central retinal vein occlusion. Ophthalmic Surg Lasers 2000;31:162-5.
11. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001;108:2249-57.
12. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999;30:427-34.
13. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 1999;128:739-46.
14. Coll GE, Sparrow JR, Marinovic A, et al. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995;15:319-26.
15. Bloodworth JM Jr, Gutgesell HP Jr, Engerman RL. Retinal vasculature of the pig. Light and electron microscope studies. Exp Eye Res 1965;4:174-8.
16. Elman MJ, Raden RZ, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc. 2001;99:219-21; discussion 22-3).
17. Hrach CJ, Johnson MW, Hassan AS, et al. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol 2000;118:659-63.
18. Irvine WD, Johnson MW, Hernandez E, et al. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991;109:718-22.
19. Johnson MW, Olsen KR, Hernandez E, et al. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990;108:259-63.
20. Benner JD, Morse LS, Toth CA, et al. Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. Arch Ophthalmol 1991;109:1731-6.
21. Chen SN, Yang TC, Ho CL, et al. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology 2003;110:704.
22. Nehemy MB, Passos E. Intravitreal recombinant tissue plasminogen activator (rt-PA) in experimental retinal vein occlusion in rabbits. Invest Ophthalmol Vis Sci ARVO E-Abstract, 2002:3524.
23. Glacet-Bernard A, Kuhn D, Vine AK, et al. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol 2000;84:609-13.
24. Folk K, Hershey JM, Rivers MB. Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy. Arch Ophthalmol 1991;109:614.
25. Weizer JS, Fekrat S. Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2003;34:350-2.
26. Mahmoud T, Fekrat S. Ischemic central retinal vein occlusion in a patient with anticardiolipid antibodies on coumadin responds to intravitreal tPA [ARVO abstract]. Invest Ophthalmol Vis Sci 2001;53:S1270.
27. Ghazi NG, Noureddine BN, Haddad RS, et al. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina 2003;23:780-84.
28. Ringleb PA, Schellinger PD, Schranz C, et al. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful? Stroke 2002;33:1437-41.
29. Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-50.
30. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-77.